Takeda Pharmaceutical (TAK) Acquisitions (2018 - 2021)

Takeda Pharmaceutical has reported Acquisitions for 4 years, with the latest figure at -$194.6 million in Q4 2021.

• On a quarterly basis, Acquisitions changed N/A year-over-year to -$194.6 million in Q4 2021; TTM through Mar 2022 was -$446.3 million, a N/A change from a year earlier, with the FY2022 full-year figure at -$442.4 million, changed N/A from the prior year.
• Acquisitions was -$194.6 million for Q4 2021 at Takeda Pharmaceutical, up from -$251.7 million in the prior quarter.
• The five-year high for Acquisitions was $652350.4 in Q3 2019, with the low at -$26.3 billion in Q1 2019.
• Average Acquisitions over 4 years is -$3.1 billion, with a median of -$97.2 million recorded in 2018.
• The largest YoY upside for Acquisitions was 101.07% in 2019 against a maximum downside of 26912.04% in 2019.
• Over 4 years, Acquisitions stood at -$60.9 million in 2018, then surged by 101.07% to $652350.4 in 2019, then sank by 522.37% to -$2.8 million in 2020, then tumbled by 6963.45% to -$194.6 million in 2021.
• The last three Acquisitions figures came in at -$194.6 million (Q4 2021), -$251.7 million (Q2 2021), and -$2.8 million (Q1 2020), per Business Quant data.